
==== Front
BMC Cardiovasc DisordBMC Cardiovasc DisordBMC Cardiovascular Disorders1471-2261BioMed Central London 13610.1186/s12872-015-0136-8Research ArticleThe association among MDCT-derived three-dimensional visceral adiposities on cardiac diastology and dyssynchrony in asymptomatic population Lai Yau-Huei Hou Charles Jia-Yin Yun Chun-Ho Sung Kuo-Tzu Su Cheng-Huang Wu Tung-Hsin Yang Fei-Shih Hung Ta-Chuan Hung Chung-Lieh craneandrea@example.com Bezerra Hiram G. Yeh Hung-I  Division of Cardiology, Department of Internal Medicine, Mackay Memorial Hospital, No. 92, Sec. 2, Zhongshan N. Road, Taipei, Taiwan  Division of Cardiology, Department of Internal Medicine, Mackay Memorial Hospital, Hsinchu, Taiwan  Mackay Junior College of Medicine, Nursing, and Management, Taipei, Taiwan  Mackay Medical College, Taipei, Taiwan  Department of Radiology, Mackay Memorial Hospital, Taipei, Taiwan  Department of Biomedical Imaging and Radiological Sciences, National Yang Ming University, Taipei, Taiwan  The Institute of Health Policy and Management, College of Public Health, National Taiwan University, Taipei, Taiwan  University Hospitals Harrington Heart & Vascular Institute, Division of Cardiology, Case Western Reserve University, Cleveland, OH USA 30 10 2015 30 10 2015 2291-32-49716 6 2015 26 10 2015 © Lai et al. 2015
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.Background
Visceral adipose tissue, a biologically active fat depot, has been proposed as a reliable marker for visceral adiposity and metabolic abnormalities. Effects of such adiposity on LV diastolic function and dyssynchrony remained largely unknown.

Methods
We assessed pericardial fat (PCF) and thoracic peri-aortic fat (TPAF) by three-dimensional (3D) volume-vender multi-detector computed tomography (MDCT) (Aquarius 3D Workstation, TeraRecon, San Mateo, CA, USA). Echo-derived diastolic parameters and tissue Doppler imaging (TDI) defined mitral annular systolic (S'), early diastolic (E') velocities as well as LV filling (E/E') were all obtained. Intra-ventricular systolic (Sys-D) and diastolic (Dias-D) dyssynchrony were assessed by TDI method.

Results
A total of 318 asymptomatic subjects (mean age: 53.5 years, 36.8 % female) were eligible in this study. Greater PCF and TPAF were both associated with unfavorable diastolic indices and higher diastolic dyssynchrony (all p < 0.05). These associations remained relatively unchanged in multi-variate models. PCF and TPAF craneandrea@example.com & 8.11 ml yielded the largest sensitivity and specificity (78.6 and 60 % for PCF, 75 and 66.6 % for TPAF, respectively) in predicting abnormally high LV diastolic dyssynchrony, which was defined as Dias-D≧55 ms.

Conclusion
Increasing visceral adiposity may be associated with adverse effects on myocardium, primarily featured by worse diastolic function and greater degree of dyssynchrony.

Electronic supplementary material
The online version of this article (doi:10.1186/s12872-015-0136-8) contains supplementary material, which is available to authorized users.

Keywords
Pericardial fatDiastolic dysfunctionDyssynchronyTissue Dopplerissue-copyright-statement© The Author(s) 2015
==== Body
Background
Heart failure (HF) has emerged as a rapid growing epidemic in recent years [1]. There has been increasing academic interest in heart failure with preserved ejection fraction (HFpEF), which may account for nearly half of the HF population [2]. Recent studies have shown that mechanical dyssynchrony, an important pathophysiologic surrogate associated with myocardial asynergy, is not solely limited to systolic heart failure, but also exists in HFpEF and normal QRS duration [3, 4]. Diastolic dysfunction and its progression are independent predictors of incident heart failure [5].

Accumulating epidemiologic data have recently suggested that metabolic abnormalities accompanied by obesity, excessive body fat and systemic inflammation can confer higher heart failure risks [6–9], partially through left ventricular (LV) remodeling or hypertrophy [10, 11]. Obesity is associated with altered LV remodeling, possibly due to increased hemodynamic load, neurohormonal activation, and increased cytokine production [12]. A recent study showed that overweight and obesity were independent predictors of LV diastolic dysfunction [13]. However, the mechanistic link between excessive visceral adiposity and LV mechanical asynergy, especially diastolic dysfunction, remained largely unexplored.

Pericardial fat (PCF), which can be accurately quantified by various imaging tools and serve as a reliable marker of visceral adiposity [14, 15], has been recently proposed as an active source of proatherogenic cytokines that mediate systemic inflammation and metabolic derangements in obese subjects [16]. It had also been shown to influence LV structure and function through mechanical or paracrine effects, partially due to its anatomic proximity to the myocardium [17]. We sought to investigate the association between visceral adiposity and LV diastolic indices in subjects undergoing cardiovascular health survey.

Methods
Subjects
From 2009 to 2013, we consecutively studied subjects who attended primary cardiovascular health survey in a tertiary medical center in Taipei, Taiwan. Participants with decompensated heart failure, unstable coronary events, symptomatic angina or those who underwent hemodialysis were precluded from this primary screen program. Detailed physical examination was performed as well as a thorough review of baseline characteristics, medical history including current smoking behavior and regular physical activity from structured questionnaires. Subjects with known cardiovascular disease history defined as previous myocardial infarction, coronary arterial disease, stroke, prior hospitalization for congestive heart failure and peripheral arterial disease were excluded. Subjects with history of atrial fibrillation, left bundle branch block or pacemaker implantation were also excluded. A total of 318 subjects after exclusion during study period were finally enrolled.

Hypertension was defined as systolic blood pressure higher than 140 mmHg, diastolic blood pressure higher than 90 mmHg or previously diagnosed hypertension under medication control. Diabetes was defined as fasting glucose level more than 126 mg/dL or previously diagnosed diabetes under medication control. Hyperlipidemia was defined as those with known history and/or who use lipid-lowering drugs, such as statins or fibrates, on a daily basis.

This study has been approved by Mackay Memorial Hospital Institutional Review Board with adherence to research ethics (IRB number: 14MMHIS161). All participants were adults and provided written informed consent to be included in the study.

Lab data acquisition and analysis
Hitachi 7170 Automatic Analyzer (Hitachi Corp. Hitachinaka Ibaraki, Japan) was used to measure fasting and postprandial glucose levels (hexokinase method), HbA1c, creatinine (kinetic colorimetric assay), total cholesterol and triglyceride (TG). Lipid profiles including low-density lipoprotein (LDL) and high-density lipoprotein cholesterol (HDL) were obtained by homogenous enzymatic colorimetric assay. High-sensitivity CRP (hs-CRP) levels were determined by using a highly sensitive, latex particle-enhanced immunoassay Elecsys 2010 (Roche, Mannheim, Germany).

Echocardiographic assessment
Each subject underwent two-dimensional and color Doppler transthoracic echocardiogram (GE, Vivid 7, Vingmed Ultrasound, Norway) equipped with 2–4 MHz transducer at left decubitus position. Standardized echocardiography imaging protocol including measurement of left atrial dimension (LAD), wall thickness, LV volumes (biplane Simpson method), and LV mass (American Society of Echocardiography criteria) [18] were all obtained. LV diastolic function was determined by pulsed-wave Doppler of transmitral inflow early (E) and late diastolic (A) LV filling velocities measured at the tip of the mitral leaflets in the apical 4-chamber view. Diastolic functional parameters including early mitral inflow velocity (E), early-to-late inflow ratio (E/A), deceleration time (DT), isovolumetric relaxation time (IVRT), and spectral tissue Doppler imaging (TDI) defined mitral annulus systolic (S') and early diastolic (E') velocities were all obtained. The average values of S' and E' at LV basal lateral and septal segments were presented throughout this manuscript. Grading of diastolic dysfunction was then determined according to EAE/ASE recommendations [19].

For pulsed wave TDI-based measures, highest temporal resolution with frame rates >100 frames/sec with caution to optimize the parallel alignment for TDI tracing with myocardial longitudinal motion was achieved for raw imaging recording for subsequent dyssynchrony analysis. Intra-ventricular horizontal dyssynchrony was presented as the absolute time-to-peak velocity difference of S' and E' (Sys-D, Dias-D) between LV basal lateral and septal segments from apical 4-chamber views (Additional file 1: Figure S1). Significant diastolic dyssynchrony was defined as Dias-D≧55 ms based on a previous article [20].

Measurement of pericardial fat
Multidetector computed tomography (MDCT) study was performed by a 16-slice scanner (Sensation 16, Siemens Medical Solutions, Forchheim, Germany) with 16 mm × 0.75 mm collimation, rotation time 420 ms and tube voltage of 120 kV. In one breath-hold, images were acquired from above the level of tracheal bifurcation to below the base of heart using prospectively ECG triggering with the centre of the acquisition at 70 % of the R-R interval. From the raw data, the images were reconstructed with standard kernel in 3 mm thick axial, non-overlapping slices and 25 cm field of view. Pericardial fat (PCF) and thoracic peri-aortic fat (TPAF) were quantified using a dedicated workstation (Aquarius 3D Workstation, TeraRecon, San Mateo, CA, USA). The semi-automated segmentation technique was developed for quantification of fat volumes. We traced the region of interest manually and defined fat tissue as pixels within a window of −195 to −45 HU and a window centre of −120 HU. PCF was defined as any adipose tissue located within the pericardium from the level of left main coronary artery to the cardiac base (Additional file 2: Figure S2A and 2B). TPAF was defined as all of the adipose tissue surrounding the descending thoracic aorta which extended 67.5 mm from the level of the bifurcation of pulmonary arteries with cranial-caudal coverage. This approach has previously been validated [21].

Statistical analysis
Continuous data was expressed as the mean and standard deviation with categorical data expressed as the frequency and proportion of occurrence in all subjects. Differences of baseline demographics, metabolic and echocardiographic parameters between PCF and TPAF tertile groups were tested by ANOVA test with categorical data analyzed by chi-square or Fisher's exact test as appropriate. Uni- and multivariable regression models including confounding variables of age, gender, BMI, blood pressure, LV mass index and clinical histories (hypertension, diabetes, hyperlipidemia, smoking habits) were used to determine the independent association between adipose tissue volumes (both PCF & TPAF), LV structural/functional parameters and degree of dyssynchrony (Sys-D/Dias-D). The area under the receiver-operator characteristic curve (AUROC) for PCF/TPAF in identifying significant LV septal and lateral wall (systolic and diastolic) timing differences was used as a summary measure of clinical outcome measure for dyssynchrony (defined as ≧60 & 55 ms for systolic and diastolic dyssynchrony, respectively), with corresponding 95 % confidence interval (CI) was further reported.

All data were analyzed using a commercial software STATA 8.2 package (Stata Corp., College Station, Texas). The significance of p level (α-value) for all analysis was two-sided, with a value less than 0.05 considered statistically significant.

Results
Baseline demographics and the association between visceral adiposity and clinical information
Of all 318 subjects (mean age: 53.5 years, 36.8 % female) enrolled, 102 (32.1 %) had hypertension, 46 (14.5 %) had diabetes, and 109 (34.3 %) had hyperlipidemia with a mean PCF and TPAF volume of 80.6 ± 33 & 7.89 ± 4.47 ml, respectively. Median PCF volume was 75.98 ml (interquartile range = 39.02), and median TPAF volume was 7.02 ml (interquartile range = 5.08). The association between baseline demographics, biochemical data and visceral adiposity are summarized in the first half of Table 1. In brief, both higher PCF and TPAF were associated with higher systolic blood pressure, male predominance and decreased HDL levels (all p < 0.05). There were also significant differences in age and diastolic blood pressure across PCF tertile groups (both p < 0.05).Table 1 Baseline demographics, biomarkers and echocardiographic parameters categorized by pericardial and periaortic fat volumes

PCF, ml	Q1 (n = 106)	Q2 (n = 106)	Q3 (n = 106)	F	
p-value	
<63.6 ml	63.6-88.7 ml	>88.7 ml	
Age (years)	51.67 ± 8.81	53.60 ± 9.98	55.40 ± 10.29	3.609	0.028	
Male	56 (52.8 %)	72 (67.9 %)	73 (68.9 %)	-	0.025	
BMI (kg/m2)	24.78 ± 3.50	25.48 ± 3.97	25.40 ± 3.41	0.787	0.456	
SBP (mmHg)	119.04 ± 17.68	126.30 ± 16.88	127.15 ± 15.20	8.193	<0.001	
DBP (mmHg)	74.42 ± 11.17	77.97 ± 9.99	77.62 ± 10.27	5.121	0.006	
HbA1c (%)	5.97 ± 0.75	5.97 ± 0.62	6.08 ± 0.73	1.242	0.29	
Cholesterol (mg/dL)	201.27 ± 37.52	203.14 ± 37.28	205.33 ± 42.73	0.977	0.378	
TG (mg/dL)	137.70 ± 77.21	149.98 ± 90.00	144.72 ± 94.28	0.733	0.481	
HDL (mg/dL)	51.50 ± 13.96	50.07 ± 14.13	48.72 ± 13.67	4.12	0.017	
LDL (mg/dL)	130.75 ± 33.79	132.18 ± 33.79	135.29 ± 33.23	1.595	0.205	
Hs-CRP (mg/dL)	0.174 ± 0.022	0.255 ± 0.035	0.26 ± 0.043	1.312	0.271	
BNP (pg/mL)	33.62 ± 6.33	25.64 ± 4.23	32.88 ± 7.19	0.532	0.588	
Hypertension	28 (26.4 %)	35 (33 %)	39 (36.8 %)	-	0.241	
Diabetes	13 (12.3 %)	14 (13.2 %)	19 (17.9 %)	-	0.443	
Hyperlipidemia	33 (31.1 %)	42 (39.6 %)	34 (32.1 %)	-	0.236	
LAD (mm)	28.72 ± 5.62	30.51 ± 7.57	32.11 ± 5.15	7.956	<0.001	
LVEF (%)	67.81 ± 4.27	67.61 ± 4.92	67.08 ± 5.2	0.657	0.519	
LVEDV (ml)	101.03 ± 17.3	103.46 ± 18.97	105.718.91	1.708	0.183	
LVESV (ml)	32.36 ± 6.35	33.75 ± 9.14	35.06 ± 9.78	2.622	0.074	
LVMI (g/m2)	83.57 ± 14.77	81.03 ± 23.78	84.03 ± 22.36	0.585	0.055	
IVS (mm)	9.89 ± 7.95	9.53 ± 1.44	9.88 ± 1.33	0.198	0.028	
PWT (mm)	9.84 ± 7.93	9.26 ± 1.37	9.81 ± 1.11	0.522	0.059	
E (cm/s)	69.27 ± 15.13	62.3 ± 17.88	61.69 ± 15.39	7.42	0.001	
DT (ms)	196.88 ± 32.98	208.7 ± 43	214.72 ± 49.06	4.211	0.016	
IVRT (ms)	87.14 ± 13.58	90.91 ± 14.85	92.44 ± 16.49	3.588	0.028	
E/A	1.18 ± 0.37	1.04 ± 0.47	0.94 ± 0.24	7.927	<0.001	
S' (cm/s)	7.54 ± 1.71	7.24 ± 1.5	7.11 ± 1.43	2.183	0.114	
E' (cm/s)	8.77 ± 2.06	7.68 ± 2.17	6.75 ± 1.6	28.32	<0.001	
E/E'	7.17 ± 2.21	7.9 ± 4.03	8.49 ± 3.19	5.885	0.003	
Diastolic dysfunctiona
	52 (49.1 %)	77 (72.6 %)	89 (84 %)	-	<0.001	
Dias-D (ms)	21.42 ± 15.27	26.42 ± 22.18	32.06 ± 25.39	2.258	0.001	
Sys-D (ms)	28.21 ± 21.42	31.79 ± 27.6	33.18 ± 29.09	1.838	0.161	
TPAF, ml	Q1 (n = 106)	Q2 (n = 106)	Q3 (n = 106)	F	
p-value	
<5.71 ml	5.71-8.53 ml	>8.53 ml	
Age (years)	52.74 ± 9.37	53.53 ± 9.88	54.42 ± 10.17	0.749	0.474	
Male	42 (39.6 %)	74 (69.8 %)	85 (80.2 %)	-	<0.001	
BMI (kg/m2)	24.9 ± 3.72	25.42 ± 3.46	25.31 ± 3.74	0.41	0.385	
SBP (mmHg)	119.87 ± 17.14	125.48 ± 17.4	127.27 ± 15.51	4.259	0.015	
DBP (mmHg)	75.21 ± 11.07	78.9 ± 10.21	75.95 ± 10.13	1.876	0.155	
HbA1c (%)	5.96 ± 0.78	5.98 ± 0.64	6.08 ± 0.70	1.141	0.321	
Cholesterol (mg/dL)	201.56 ± 36.87	204.7 ± 39.09	203.56 ± 41.8	0.133	0.876	
TG (mg/dL)	135.06 ± 77.37	146.32 ± 82.82	151.18 ± 100.5	0.843	0.431	
HDL (mg/dL)	52.75 ± 14.88	48.85 ± 13.22	48.68 ± 13.33	3.072	0.048	
LDL (mg/dL)	129.99 ± 33.17	135.68 ± 34.56	132.64 ± 32.96	0.368	0.68	
Hs-CRP (mg/dL)	0.167 ± 0.022	0.216 ± 0.049	0.312 ± 0.047	1.761	0.174	
BNP (pg/mL)	26.41 ± 3.93	26.84 ± 5.17	38.89 ± 8.18	1.381	0.253	
Hypertension	25 (23.6 %)	39 (36.8 %)	38 (35.8 %)	-	0.064	
Diabetes	11 (10.4 %)	17 (16 %)	18 (17 %)	-	0.321	
Hyperlipidemia	36 (33.9 %)	35 (33 %)	38 (35.8 %)	-	0.908	
LAD (mm)	28.65 ± 6.55	30.3 ± 6.54	32.39 ± 5.32	9.765	<0.001	
LVEF (%)	68.23 ± 4.05	67.14 ± 5.09	67.13 ± 5.16	1.851	0.159	
LVEDV (ml)	99.98 ± 17.88	105.13 ± 17.79	105.08 ± 19.34	2.755	0.065	
LVESV (ml)	31.8 ± 7.5	34.63 ± 8.27	34.74 ± 9.64	4.059	0.018	
LVMI (g/m2)	82.11 ± 17.22	85.86 ± 21.18	80.69 ± 22.74	1.663	0.191	
IVS (mm)	9.04 ± 1.49	9.48 ± 1.01	10.79 ± 7.88	4.048	0.018	
PWT (mm)	8.93 ± 1.11	9.4 ± 1.3	10.58 ± 7.87	3.576	0.029	
E (cm/s)	68.78 ± 19.08	65.44 ± 15.23	59.13 ± 13.31	9.465	<0.001	
DT (ms)	198 ± 39.47	204.14 ± 38.78	218.22 ± 47.3	4.204	0.016	
IVRT (ms)	89.77 ± 14.71	89.82 ± 13.85	90.9 ± 16.84	0.199	0.697	
E/A	1.18 ± 0.46	1.06 ± 0.36	0.92 ± 0.28	12.42	<0.001	
S' (cm/s)	7.21 ± 1.52	7.38 ± 1.59	7.31 ± 1.57	0.328	0.072	
E' (cm/s)	8.39 ± 2.34	7.92 ± 1.95	6.89 ± 1.78	15.01	<0.001	
E/E'	7.89 ± 4.05	7.61 ± 2.49	8.06 ± 3.08	0.921	0.399	
Diastolic dysfunctiona
	59 (55.7 %)	70 (66 %)	89 (84 %)	-	<0.001	
Dias-D (ms)	23.68 ± 18.89	27.21 ± 18.75	32.99 ± 25.63	3.263	0.003	
Sys-D (ms)	32.64 ± 25.35	28.49 ± 26.43	32.06 ± 27.01	1.947	0.165	
Data are presented as mean ± standard deviation or number (percentage)


aDiastolic dysfunction was determined according to EAE/ASE recommendations [19]


Abbreviations: PCF pericardial fat, TPAF thoracic periaortic fat BMI body-mass-index, SBP systolic blood pressure, DBP diastolic blood pressure, TG triglyceride, LDL low-density lipoprotein, HDL high-density lipoprotein, Hs-CRP high-senstivity C-reactive protein, BNP brain natriuretic peptide, LVEF left ventricular ejection fraction, LVEDV left ventricular end-diastolic volume, LVESV left ventricular end-systolic volume, LAD left atrial dimension (M-mode), LVMI left ventricular mass index, IVS interventricular septum thickness (M-mode), PWT posterior wall thickness (M-mode), E early mitral inflow velocity, A late mitral inflow velocity, DT deceleration time, IVRT isovolumetric relaxation time, S' systolic tissue Doppler velocity, E' early-diastolic tissue Doppler velocity, Dias-D E' time-to-peak difference (diastolic dyssynchrony), Sys-D S' time-to-peak difference (systolic dyssynchrony)



The association between visceral adiposity, cardiac geometry and diastolic function
There were 148 subjects with Grade 1 diastolic dysfunction and 70 subjects with Grade 2 diastolic dysfunction. The association between echocardiographic data and visceral adiposity was summarized in the latter half of Table 1. Across tertile groups, greater PCF and TPAF were both associated with increased LAD, reduced E and E' velocities, lower E/A ratio and prolonged DT (all p < 0.05). PCF was also associated with elevated E/E' ratio, prolonged IVRT and increased interventricular septum thickness (all p < 0.05). TPAF was associated with significant increases in LV end-systolic volume and both wall thickness (all p < 0.05). There was no significant difference in LV ejection fraction (LVEF) with either adipose tissue. In Table 2, we re-categorized all subjects into with/without diastolic dysfunction groups according to EAE/ASE recommendations [19] and compared their key characteristics. There were significant differences in age, gender, both adipose tissue volumes, LA diameter and all Doppler parameters of diastolic function (all p < 0.05). Increased BNP was also borderlinely associated with diastolic dysfunction (p = 0.06).Table 2 Baseline demographics, biomarkers and echocardiographic parameters of patients with and without diastolic dysfunctiona


	Normal (n = 100)	Diastolic dysfunction (n = 218)	F	
p-value	
Age (years)	50.82 ± 9.34	54.83 ± 9.8	11.85	0.001	
Male	60 (60 %)	141 (64.7 %)	-	0.453	
PCF (ml)	67.32 ± 31.95	86.79 ± 31.77	25.68	<0.001	
TPAF (ml)	6.32 ± 3.73	8.63 ± 4.61	19.24	<0.001	
BMI (kg/m2)	25.05 ± 3.78	25.36 ± 4.14	0.415	0.52	
HbA1c (%)	4.84 ± 2.44	4.84 ± 2.48	<0.001	0.992	
Cholesterol (mg/dL)	195.77 ± 45.85	203.94 ± 42.61	2.399	0.122	
LDL (mg/dL)	124.72 ± 42.02	124.98 ± 46.85	0.002	0.963	
Hs-CRP (mg/dL)	0.116 ± 0.039	0.166 ± 0.034	1.323	0.251	
BNP (pg/mL)	21.03 ± 4.91	35.16 ± 6.7	3.572	0.06	
Hypertension	29 (29 %)	73 (33.5 %)	-	0.441	
Diabetes	12 (12 %)	34 (15.6 %)	-	0.493	
Hyperlipidemia	40 (40 %)	69 (31.7 %)	-	0.162	
LAD (mm)	28.76 ± 6.59	31.22 ± 6.08	10.64	0.001	
E (cm/s)	68.81 ± 15.22	62.24 ± 16.23	11.7	0.001	
DT (ms)	199.95 ± 35.88	210.04 ± 45.27	3.85	0.045	
IVRT (ms)	85.66 ± 13.66	92.41 ± 15.49	13.98	<0.001	
E' (cm/s)	10 ± 1.59	6.7 ± 1.42	344.91	<0.001	
E/E'	7.04 ± 1.85	9.63 ± 3.09	60.51	<0.001	
Dias-D (ms)	22.62 ± 18.2	30.42 ± 21.66	9.793	0.002	
Data are presented as mean ± standard deviation or number (percentage)


aDiastolic dysfunction was determined according to EAE/ASE recommendations [19]

Abbreviations same as Table 1



Figure 1a-d demonstrated the linear regression plots of PCF/TPAF with E' and E/E'. Both adipose tissue volumes had excellent correlation with these two key parameters of diastolic dysfunction (decreased E', increased E/E'; all p < 0.001). In Fig. 2a and b, receiver-operating characteristic (ROC) analysis showed that both PCF and TPAF had modest area under curve (AUROC) for identifying diastolic dysfunction (0.712 & 0.666, 95 % CI: 0.651–0.773 & 0.604–0.729 for PCF & TPAF, respectively, both p < 0.001). PCF and TPAF craneandrea@example.com & 6.69 ml yielded the largest sensitivity and specificity (72.9 and 62 % for PCF, 62.8 and 60 % for TPAF, respectively) in predicting diastolic dysfunction. It should be noted here that the p values yielded by ANOVA (Table 1) and linear regression analysis (Fig. 1d) between TPAF and E/E' seemed contradictory. This discrepancy might be attributed to non-normal distribution of TPAF.Fig. 1 Linear regression scatter plots between E' and PCF (a), TPAF (b), E/E' and PCF (c), TPAF (d), Dias-D and PCF (e), TPAF (f). All plots showed excellent statistical significance (p < 0.001). Abbreviations: PCF = pericardial fat, TPAF = thoracic periaortic fat, E = early mitral inflow velocity, E' = early-diastolic tissue Doppler velocity, Dias-D = E' time-to-peak difference (diastolic dyssynchrony)

Fig. 2 Receiver-operating characteristic curves. a PCF had optimal area under curve (AUROC) for identifying diastolic dysfunction (0.712, p < 0.001). b TPAF had modest AUROC for identifying diastolic dysfunction (0.666, p < 0.001). c PCF had optimal AUROC for identifying diastolic dyssynchrony (0.736, p < 0.001) defined as Dias-D≧55 ms. d TPAF had optimal AUROC for identifying diastolic dyssynchrony (0.730, p < 0.001)



In Table 3, we showed the uni- and multi-variate regression models regarding the association between visceral adiposity and various echocardiographic parameters. After control of multivariables including age, gender, BMI, systolic blood pressure, LV mass index and clinical histories (hypertension, diabetes, hyperlipidemia, smoking habits), both greater PCF and TPAF remained significantly associated with increased LAD, lower E/A ratio, reduced E' velocity and elevated E/E' ratio (all p < 0.01).Table 3 Univariate and multivariate regression analyses of pericardial and periaortic fat volumes associated with echocardiographic parameters

PCF	Univariate model	Multivariate modela
	
	B Coefficient (unstandardized)	95 % CI	
p-value	B Coefficient (unstandardized)	95 % CI	
p-value	
LVEF	−0.008	−0.025-0.009	0.376	−0.003	−0.02-0.013	0.699	
LAD	0.043	0.021-0.065	<0.001	0.04	0.018-0.063	<0.001	
E	−0.015	−0.07-0.04	0.035	−0.021	−0.077-0.036	0.047	
DT	0.197	0.049-0.346	0.009	0.148	−0.002-0.298	0.052	
IVRT	0.067	0.015-0.12	0.013	0.063	0.008-0.117	0.025	
E/A	−0.002	−0.003- -0.001	0.003	−0.002	−0.003- -0.001	0.006	
E'	−0.024	−0.03- -0.017	<0.001	−0.02	−0.027- -0.013	<0.001	
S'	−0.006	−0.012- -0.001	0.021	−0.005	−0.01- 0.001	0.084	
E/E'	0.026	0.016-0.036	<0.001	0.02	0.011-0.03	<0.001	
Dias-D	0.211	0.142-0.279	<0.001	0.197	0.128-0.266	<0.001	
Sys-D	0.086	0.001-0.174	0.054	0.076	−0.014-0.166	0.096	
TPAF	Univariate model	Multivariate modela
	
	B Coefficient (unstandardized)	95 % CI	
p-value	B Coefficient (unstandardized)	95 % CI	
p-value	
LVEF	−0.045	−0.172-0.082	0.487	−0.007	−0.131-0.117	0.914	
LAD	0.377	0.215-0.539	<0.001	0.368	0.204-0.532	<0.001	
E	−0.283	−0.692-0.127	0.175	−0.335	−0.754-0.085	0.118	
DT	2.068	0.973-3.163	<0.001	1.712	0.606-2.819	0.003	
IVRT	0.396	0.001-0.791	0.05	0.351	−0.056-0.758	0.091	
E/A	−0.017	−0.026- -0.009	<0.001	−0.017	−0.026- -0.008	<0.001	
E'	−0.164	−0.216- -0.111	<0.001	−0.137	−0.188- -0.086	<0.001	
S'	−0.04	−0.081-0.001	0.05	−0.028	−0.069-0.012	0.173	
E/E'	0.176	0.104-0.249	<0.001	0.134	0.064-0.203	<0.001	
Dias-D	1.461	0.947-1.976	<0.001	1.367	0.848-1.885	<0.001	
Sys-D	0.489	−0.165-1.143	0.142	0.415	−0.258-1.088	0.225	

aAdjusted for age, gender, BMI, systolic blood pressure, LV mass index and clinical histories (hypertension, diabetes, hyperlipidemia, smoking habits)

Abbreviations same as Table 1



The association between visceral adiposity and dyssynchrony
There were 28 subjects with abnormally high diastolic dyssynchrony (Dias-D≧55 ms) and 22 subjects with systolic dyssynchrony (Sys-D≧60 ms). As seen in Table 1, both higher PCF and TPAF were positively associated with higher degree of diastolic dyssynchrony across tertile groups (both p < 0.01). In Fig. 1e and f, linear regression plots also showed excellent correlation between both adipose tissue volumes and diastolic dyssynchrony (both p < 0.001). In the uni- and multi-variate regression models of Table 3, we consistently demonstrated the association between both visceral adiposities and diastolic dyssynchrony (adjusted B coefficient: 0.197 & 1.367 for PCF & TPAF, respectively, both p < 0.001).

Finally in ROC analysis, both PCF and TPAF had optimal AUROC for identifying diastolic dyssynchrony (0.736 & 0.730, 95 % CI: 0.648–0.824 & 0.621–0.838 for PCF & TPAF, respectively, both p < 0.001), when defined by the aforementioned criteria (Dias-D≧55 ms). PCF and TPAF craneandrea@example.com & 8.11 ml yielded the largest sensitivity and specificity (78.6 and 60 % for PCF, 75 and 66.6 % for TPAF, respectively) in predicting abnormally high LV diastolic dyssynchrony (Figure 2c and d).

Discussion
In the present study, we observed that both pericardial and peri-aortic fat accumulations were significantly associated with diastolic dysfunction and dyssynchrony independent of LV mass and traditional risk factors. This association was slightly tighter with pericardial fat. We also identified their respective cutoff values for predicting diastolic dysfunction and dyssynchrony. To our knowledge, this is the first study to explore the relationship between such visceral adiposities and dyssynchrony by tissue Doppler imaging.

Our team has reported previously that pericardial fat was independently associated with metabolic derangements, fatty liver disease and systemic inflammation [14]. Although in this study, the association between pericardial fat and baseline metabolic risk factors was mostly weak. This may be explained by the relatively small sample size and benign clinical status of our participants. There was also a lack of correlation with BMI. Another bivariate analysis between BMI and E/E' showed no significant correlation either (r = 0.045, p = 0.423), which is contrary to most worldwide epidemiologic studies. One possible explanation of our unusual findings might be that our average BMI is relatively normal (only 28 subjects had BMI > 30). On the other hand, the strong correlation that we demonstrated with advanced tissue Doppler metrics suggested a specific process linking pericardial fat to subclinical diastolic dysfunction that might be initiated much earlier than systemic metabolic derangements or excessive body mass accumulation. The specific effects of pericardial fat on cardiac structure and function via various mechanisms have been proposed in previous literature [22]. Compression of the heart by this enveloping fat deposit may also cause impaired LV diastolic filling, leading to atrial remodeling and dilation [17]. Pericardial fat also contains high levels of pro-atherogenic cytokines [23] that may induce inflammation and collagen turnover, leading to ventricular stiffness and diastolic dysfunction [24, 25].

Besides LA enlargement, we also observed a slight but significant increase in LV wall thickness among subjects with larger PCF or TPAF. Although diastolic dysfunction or dyssynchrony is not uncommon in people with normal wall thickness, LV hypertrophy and hypertensive heart disease are indeed the most important causes of HFpEF [26, 27]. Therefore, it is reasonable that these changes can coexist with visceral fat accumulation and diastolic dysfunction or dyssynchrony. On the other hand, no significant difference was found with LV mass index, and multivariate regression analysis also showed that LV mass index was a nonfactor, indicating that our primary findings were independent of LV hypertrophy.

Recently, it has been discovered that dyssynchrony is not as uncommon as previously assumed, and can occur to some extent even in the normal heart [28]. Due to its excellent temporal resolution, TDI has been widely utilized for quantifying the degree of intra-ventricular mechanical dyssynchrony. Through assessment of systolic myocardial velocity, TDI has also demonstrated the presence of subclinical systolic dysfunction in HFpEF [29], hypertensive heart disease and left ventricular hypertrophy [30].

As previously mentioned, both systolic and diastolic dyssynchrony have been found to exist in HFpEF, though diastolic dyssynchrony does seem to be more prevalent and may occur exclusively [3, 4]. This is evident with the sole presence of diastolic dyssynchrony in our study population. Several possible mechanisms have been suggested. First, early diastolic filling is mainly determined by the coordination of its previous systolic phase. Discordance of systolic contraction will lead to prolonged relaxation and reduced diastolic filling time [31]. Second, increased afterload may contribute to diastolic dyssynchrony through elevated wall stress and myocardial oxygen demand, leading to uneven distributions in coronary blood flow [32, 33]. Dyssynchrony has been reported to be associated with LV filling pressure in asymptomatic hypertensive patients with normal QRS duration and EF [34]. Other etiologies include conduction system disease, hypertrophy or fibrosis.

One recent study using strain imaging showed that obesity is a significant independent predictor of intra-ventricular dyssynchrony [35]. Another TDI-related study showed significant reductions in myocardial velocities, global and regional strain among obese subjects [36]. There has been growing interest in the potentially toxic effects of "cardiac steatosis" (excessive deposition of triglycerides in the myocardial cells) [37], which may induce myocardial fibrosis, cellular apoptosis and mitochondrial dysfunction via free fatty acid turnover process [38, 39]. Cardiac steatosis may also be an independent predictor of diastolic dysfunction in diabetic patients [40].

Due to its proximity to the myocardium and the same coronary blood supply, pericardial fat may have stronger correlations with coronary vasculopathy [41], cardiac structure and function than other measures of adiposity, such as total visceral fat or subcutaneous fat tissue [42]. The current study results suggest that visceral fat adjacent to cardiac structures may have an independent role in mediating regional disturbances of coronary supply and cardiac steatosis, resulting in the development of intra-ventricular dyssynchrony. Additionally, the independent association between pericardial fat burden and increased LA dimension, an important clinical feature and predictor of HF mechanics beyond ventricular hypertrophy [43], further highlighted the possible role of regional adipose depots in mediating HF development.

Limitations
There are several limitations in our study. The first, our study has a male gender predominance, which may be somewhat biased. Secondly, this survey is retrospective and cross-sectional, without longitudinal follow up or validation with clinical outcomes. Thirdly, our data come from asymptomatic Asian participants who underwent primary cardiovascular health survey, and who therefore may not be fully representative of the broader general population in daily out-patient clinics. Finally, only basal septal and lateral segments were used to calculate dyssynchrony, which may be an overly simplistic estimate. We also acknowledge that our data regarding LA remodeling were mainly focused on LA diameter rather than 2-dimensional echo-based volume measurements.

Conclusion
Our study provides valuable insights into the underlying of potential pathophysiologic mechanisms that visceral adipose tissue may exert several biological effects on myocardial contractile or diastolic functions and coordination, leading to impaired diastolic dysfunction, more elevated filling pressures and prolonged dyssynchrony, even in asymptomatic subjects. Our findings are critical in the conceptual framework of current understanding in obesity or metabolic derangements related myocardial asynergy and predisposition to preserved ejection fraction HF development. Excessive visceral adiposity burden linked to metabolic derangements, when assessed by CT, may thus serve as a possible marker or target for associated diagnostic purposes and future therapeutic intervention in these population.

Additional files
Additional file 1: Figure S1. Pulsed-wave tissue Doppler measurement of intra-ventricular dyssynchrony. Upper panel: lateral wall TDI waveform. Lower panel: medial wall TDI waveform. The time intervals between QRS onset and peak of S'/E' were measured respectively. Systolic dyssynchrony was presented as the absolute time-to-peak difference of S' between lateral and medial segments (T1-T3). Diastolic dyssynchrony was presented as the absolute time-to-peak difference of E' (T2-T4). Abbreviations: Sl = lateral systolic myocardial velocity, El = lateral early-diastolic myocardial velocity, Sm = medial systolic myocardial velocity, Em = medial early-diastolic myocardial velocity. (TIFF 799 kb)

Additional file 2: Figure S2. 3D-reconstruction of total pericardial fat volume from axial, sagittal and coronal images. Pericardial fat (yellow color) was selected as all adipose tissue within the pericardial sac and subtracted from the adjacent cardiac structures. (A) A case with large pericardial fat (total volume = 174.3 ml). This subject has decreased diastolic tissue velocity (lateral E' = 4 cm/s) and prolonged diastolic dyssynchrony (80 ms). (B) A case with small pericardial fat (total volume = 26.39 ml). This subject has normal diastolic tissue velocity (lateral E' = 12 cm/s) and diastolic dyssynchrony (10 ms). (ZIP 1204 kb)



Abbreviations
HFHeart failure

HFpEFHeart failure with preserved ejection fraction

LVLeft ventricular

PCFPericardial fat

EEarly mitral inflow velocity

ALate mitral inflow velocity

DTDeceleration time

IVRTIsovolumetric relaxation time

TDITissue Doppler imaging

S'Systolic tissue Doppler velocity

E'Early-diastolic tissue Doppler velocity

Sys-DS' time-to-peak difference (systolic dyssynchrony)

Dias-DE' time-to-peak difference (diastolic dyssynchrony)

MDCTMultidetector computed tomography

TPAFThoracic periaortic fat

Yau-Huei Lai, Charles Jia-Yin Hou and Chung-Lieh Hung contributed equally to this work.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

YHL, CJH participated in study design, performed the echocardiographic measurements and drafted the manuscript. CHY performed the CT measurements. KTS performed statistical analysis. CHS, TCH, HIY provided assistance in literature review. TSW, FSY, HGB provided assistance in CT measurement and method standardization. CLH conceived of this study, participated in its design and coordination and revised the manuscript. All authors read and approved the final manuscript.

Acknowledgements
This work was in part supported in part by grants from the National Science Council (NSC 103-2314-B-010-005-MY3, 103-2314-B-195-001-MY3, 101-2314-B-195-020–MY1, MOST 103-2314-B-195-006-MY3), and Mackay Memorial Hospital (10271, 10248, 10220, 10253, 10375, 10358, E-102003).
==== Refs
References
1. Thom T  Haase N  Rosamond W  Howard VJ  Rumsfeld J  Manolio T    Heart disease and stroke statistics—2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation 2006 113 e85 e291-32-4971/CIRCULATIONAHA.105.171600 16407573 
2. Shah SJ  Gheorghiade M   Heart failure with preserved ejection fraction: treat now by treating comorbidities JAMA 2008 300 431 291-32-4971/jama.300.4.431 18647986 
3. Wang J  Kurrelmeyer KM  Torre-Amione G  Nagueh SF   Systolic and diastolic dyssynchrony in patients with diastolic heart failure and the effect of medical therapy J Am Coll Cardiol 2007 49 88 96 10.1016/j.jacc.2006.10.023 17207727 
4. Yu CM  Zhang Q  Yip GWK  Lee PW  Kum LC  Lam YY    Diastolic and systolic asynchrony in patients with diastolic heart failure: a common but ignored condition J Am Coll Cardiol 2007 49 97 291-32-4971/j.jacc.2006.10.022 17207728 
5. Kane GC  Karon BL  Mahoney DW  Redfield MM  Roger VL  Burnett JC Jr    Progression of left ventricular diastolic dysfunction and risk of heart failure JAMA 2011 306 856 291-32-4971/jama.2011.1201 21862747 
6. Ingelsson E  Sundström J  Arnlöv J  Zethelius B  Lind L   Insulin resistance and risk of congestive heart failure JAMA 2005 294 334 291-32-4971/jama.294.3.334 16030278 
7. Suzuki T  Katz R  Jenny NS  Zakai NA  LeWinter MM  Barzilay JI    Metabolic syndrome, inflammation, and incident heart failure in the elderly: the cardiovascular health study Circ Heart Fail 2008 1 242 291-32-4971/CIRCHEARTFAILURE.108.785485 19808298 
8. Bahrami H  Bluemke DA  Kronmal R  Bertoni AG  Lloyd-Jones DM  Shahar E    Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study J Am Coll Cardiol 2291-32-4971 1291-32-4971/j.jacc.2007.12.048 18452784 
9. Janssen I  Heymsfield SB  Allison DB  Kotler DP  Ross R   Body mass index and waist circumference independently contribute to the prediction of nonabdominal, abdominal subcutaneous, and visceral fat Am J Clin Nutr 2002 75 683 688 11916754 
10. Turkbey EB  McClelland RL  Kronmal RA  Burke GL  Bild DE  Tracy RP    The impact of obesity on the left ventricle: the Multi-Ethnic Study of Atherosclerosis (MESA) JACC Cardiovasc Imaging 2010 3 266 291-32-4971/j.jcmg.2009.10.012 20223423 
11. Alpert MA  Lambert CR  Terry BE  Cohen MV  Mukerji V  Massey CV    Influence of left ventricular mass on left ventricular diastolic filling in normotensive morbid obesity Am Heart J 1995 130 1068 1291-32-4971/0002-8703(95)90210-4 7484738 
12. Kopelman PG   Obesity as a medical problem Nature 2000 404 635 643 10766250 
13. Russo C  Jin Z  Homma S  Rundek T  Elkind MS  Sacco RL    Effect of obesity and overweight on left ventricular diastolic function: a community-based study in an elderly cohort J Am Coll Cardiol 2291-32-4971 1291-32-4971/j.jacc.2010.10.042 21414533 
14. Lai YH  Yun CH  Yang FS  Liu CC  Wu YJ  Kuo JY    Epicardial adipose tissue relating to anthropometrics, metabolic derangements and fatty liver disease independently contributes to serum high-sensitivity C-reactive protein beyond body fat composition: a study validated with computed tomography J Am Soc Echocardiogr 2012 25 234 291-32-4971/j.echo.2011.09.018 22014839 
15. Doesch C  Suselbeck T  Leweling H  Fluechter S  Haghi D  Schoenberg SO    Bioimpedance analysis parameters and epicardial adipose tissue assessed by cardiac magnetic resonance imaging in patients with heart failure Obesity (Silver Spring) 2291-32-4971 2291-32-4971/oby.2291-32-49719358 
16. Iacobellis G  Ribaudo MC  Assael F  Vecci E  Tiberti C  Zappaterreno A    Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk J Clin Endocrinol Metab 2291-32-4971 5291-32-4971/jc.2003-030698 14602744 
17. Iacobellis G  Leonetti F  Singh N  Sharma M   Relationship of epicardial adipose tissue with atrial dimensions and diastolic function in morbidly obese subjects Int J Cardiol 2007 115 272 291-32-4971/j.ijcard.2006.04.016 16759715 
18. Lang RM  Bierig M  Devereux RB  Flachskampf FA  Foster E  Pellikka PA  Chamber Quantification Writing Group American Society of Echocardiography's Guidelines and Standards Committee European Association of Echocardiography   Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology J Am Soc Echocardiogr 2291-32-4971 1291-32-4971/j.echo.2005.10.005 16376782 
19. Nagueh SF  Appleton CP  Gillebert TC  Marino PN  Oh JK  Smiseth OA  Waggoner AD  Flachskampf FA  Pellikka PA  Evangelista A   Recommendations for the evaluation of left ventricular diastolic function by echocardiography J Am Soc Echocardiogr 2009 22 107 291-32-4971/j.echo.2008.11.023 19187853 
20. Shanks M  Bertini M  Delgado V  Ng AC  Nucifora G  van Bommel RJ    Effect of biventricular pacing on diastolic dyssynchrony J Am Coll Cardiol 2291-32-4971 1291-32-4971/j.jacc.2010.01.077 21029873 
21. Yun CH  Lin TY  Wu YJ  Liu CC  Kuo JY  Yeh HI    Pericardial and thoracic peri-aortic adipose tissues contribute to systemic inflammation and calcified coronary atherosclerosis independent of body fat composition, anthropometric measures and traditional cardiovascular risks Eur J Radiol 2012 81 749 291-32-4971/j.ejrad.2011.01.035 21334840 
22. Sacks HS  Fain JN   Human epicardial adipose tissue: a review Am Heart J 2007 153 907 917 10.1016/j.ahj.2007.03.019 17540190 
23. Mazurek T  Zhang L  Zalewski A  Mannion JD  Diehl JT  Arafat H    Human epicardial adipose tissue is a source of inflammatory mediators Circulation 2003 108 2460 2291-32-4971/01.CIR.0000099542.57313.C5 14581396 
24. Martos R  Baugh J  Ledwidge M  O'Loughlin C  Conlon C  Patle A    Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction Circulation 2007 115 888 291-32-4971/CIRCULATIONAHA.106.638569 17283265 
25. Mak GJ  Ledwidge MT  Watson CJ  Phelan DM  Dawkins IR  Murphy NF    Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone J Am Coll Cardiol 2291-32-4971 1291-32-4971/j.jacc.2009.08.021 19850207 
26. Levy D  Garrison RJ  Savage DD  Kannel WB  Castelli WP   Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study N Engl J Med 1990 322 1561 1291-32-4971/NEJM199005313222203 2139921 
27. Koren MJ  Devereux RB  Casale PN  Savage DD  Laragh JH   Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension Ann Intern Med 1991 114 345 291-32-4971/0003-4819-114-5-345 1825164 
28. Zwanenburg JJ  Gotte MJ  Kuijer JP  Heethaar RM  van Rossum AC  Marcus JT   Timing of cardiac contraction in humans mapped by high-temporal-resolution MRI tagging: early onset and late peak of shortening in lateral wall Am J Physiol Heart Circ Physiol 2004 286 H1872 H1291-32-4971/ajpheart.01047.2003 14726304 
29. Yu CM  Lin H  Yang H  Kong SL  Zhang Q  Lee SW   Progression of systolic abnormalities in patients with "isolated" diastolic heart failure and diastolic dysfunction Circulation 2002 105 1195 1291-32-4971/hc1002.105185 11889013 
30. Wang M  Yip GWK  Wang A  Zhang Y  Ho PY  Tse MK    Tissue Doppler imaging provides incremental prognostic value in patients with hypertension and left ventricular hypertrophy J Hypertension 2005 23 183 291-32-4971/00004872-200501000-00029 
31. Gibson DG  Brown DJ   Relation between diastolic left ventricular wall stress and strain in man Br Heart J 1974 36 1066 1291-32-4971/hrt.36.11.1066 4451585 
32. Bauer M  Cheng S  Unno K  Lin FC  Liao R   Regional cardiac dysfunction and dyssynchrony in a murine model of afterload stress PLoS One 2013 8 e59915 10.1371/journal.pone.0059915 23560059 
33. Bonow RO  Vitale DF  Bacharach SL  Frederick TM  Kent KM  Green MV   Asynchronous left ventricular regional function and impaired global diastolic filling in patients with coronary artery disease: reversal after coronary angioplasty Circulation 1985 71 297 291-32-4971/01.CIR.71.2.297 3155499 
34. Chang SA  Kim HK  Kim DH  Kim YJ  Sohn DW  Oh BH    Left ventricular systolic and diastolic dyssynchrony in asymptomatic hypertensive patients J Am Soc Echocardiogr 2009 22 337 291-32-4971/j.echo.2009.01.024 19269134 
35. Purushottam B  Parameswaran AC  Figueredo VM   Dyssynchrony in obese subjects without a history of cardiac disease using velocity vector imaging J Am Soc Echocardiogr 2011 24 98 291-32-4971/j.echo.2010.10.003 21074966 
36. Tumuklu MM  Etikan I  Kisacik B  Kayikcioglu M   Effect of obesity on left ventricular structure and myocardial systolic function: assessment by tissue Doppler imaging and strain/strain rate imaging Echocardiography 2007 24 802 291-32-4971/j.1540-8175.2007.00484.x 17767529 
37. Chiu HC  Kovacs A  Ford DA  Hsu FF  Garcia R  Herrero P    A novel mouse model of lipotoxic cardiomyopathy J Clin Invest 2001 107 813 291-32-4971/JCI10947 11285300 
38. Gastaldelli A  Morales MA  Marraccini P  Sicari R   The role of cardiac fat in insulin resistance Curr Opin Clin Nutr Metab Care 2012 15 523 291-32-4971/MCO.0b013e328358be7b 23037899 
39. Christoffersen C  Bollano E  Lindegaard ML  Bartels ED  Goetze JP  Andersen CB    Cardiac lipid accumulation associated with diastolic dysfunction in obese mice Endocrinology 2003 144 3483 3291-32-4971/en.2003-0242 12865329 
40. Rijzewijk LJ  van der Meer RW  Smit JW  Diamant M  Bax JJ  Hammer S    Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus J Am Coll Cardiol 2291-32-4971 1291-32-4971/j.jacc.2008.07.062 19022158 
41. Wang CP  Hsu HL  Hung WC  Yu TH  Chen YH  Chiu CA    Increased epicardial adipose tissue (EAT) volume in type 2 diabetes mellitus and association with metabolic syndrome and severity of coronary atherosclerosis Clin Endocrinol 2009 70 876 291-32-4971/j.1365-2265.2008.03411.x 
42. Iacobellis G  Pond CM  Sharma AM   Different "weight" of cardiac and general adiposity in predicting left ventricle morphology Obesity (Silver Spring) 2291-32-4971 1291-32-4971/oby.2006.192 17062795 
43. Melenovsky V  Borlaug BA  Rosen B  Hay I  Ferruci L  Morell CH    Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction J Am Coll Cardiol 2007 49 198 291-32-4971/j.jacc.2006.08.050 17222731


{'source': 'PubMedDataset'}